Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026)

Regeneron Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $257.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 5886.05% year-over-year to $257.4 million in Q1 2026; TTM through Mar 2026 was $785.2 million, a 22.04% increase from a year earlier, with the FY2025 full-year figure at $532.1 million, down 45.86% from the prior year.
• Share-based Compensation advanced to $257.4 million in Q1 2026 per REGN's latest filing, from -$212.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $642.5 million in Q4 2023 and bottomed at -$212.3 million in Q4 2025.
• The 5-year median for Share-based Compensation is $189.1 million (2022), against an average of $182.5 million.
• Across the five-year window, Share-based Compensation tumbled 182.74% in 2023 and surged 5886.05% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $189.1 million in 2022, then jumped by 239.77% to $642.5 million in 2023, then tumbled by 52.62% to $304.4 million in 2024, then slumped by 169.74% to -$212.3 million in 2025, then jumped by 221.24% to $257.4 million in 2026.
• Per Business Quant, the three latest REGN Share-based Compensation figures stand at $257.4 million (Q1 2026), -$212.3 million (Q4 2025), and $237.0 million (Q3 2025).